215 related articles for article (PubMed ID: 32448335)
1. Combined use of apatinib mesylate and vinorelbine versus vinorelbine alone in recurrent or metastatic triple-negative breast cancer: study protocol for a randomized controlled clinical trial.
Wu S; Zhang L; Li H; Xu J; Jiang C; Sun T
Trials; 2020 May; 21(1):420. PubMed ID: 32448335
[TBL] [Abstract][Full Text] [Related]
2. The efficiency and safety of low-dose apatinib combined with oral vinorelbine in pretreated HER2-negative metastatic breast cancer.
Huang JY; Chen XL; Xie XF; Song L; Chen LP; Lan XF; Bai X; Chen X; Du CW
Cancer Med; 2024 Apr; 13(8):e7181. PubMed ID: 38659376
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
[TBL] [Abstract][Full Text] [Related]
4. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
[TBL] [Abstract][Full Text] [Related]
5. A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Zhang Q; Shao B; Tong Z; Ouyang Q; Wang Y; Xu G; Li S; Li H
BMC Med; 2022 Oct; 20(1):321. PubMed ID: 36184642
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Apatinib Plus Vinorelbine in Patients With Wild-Type Advanced Non-Small Cell Lung Cancer After Second-Line Treatment Failure: A Nonrandomized Clinical Trial.
Zhang X; Xiong Y; Xia Q; Wu F; Liu L; Zhou Y; Zeng L; Zhou C; Xia C; Jiang W; Liao D; Xiao L; Liu L; Yang H; Guan R; Li K; Wang J; Lei G; Zhang Y; Yang N
JAMA Netw Open; 2020 Mar; 3(3):e201226. PubMed ID: 32191330
[TBL] [Abstract][Full Text] [Related]
7. Does a ketogenic diet as an adjuvant therapy for drug treatment enhance chemotherapy sensitivity and reduce target lesions in patients with locally recurrent or metastatic Her-2-negative breast cancer? Study protocol for a randomized controlled trial.
Wang Y; Jing MX; Jiang L; Jia YF; Ying E; Cao H; Guo XY; Sun T
Trials; 2020 Jun; 21(1):487. PubMed ID: 32503654
[TBL] [Abstract][Full Text] [Related]
8. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
[TBL] [Abstract][Full Text] [Related]
9. A real-world study of the effectiveness and safety of apatinib-based regimens in metastatic triple-negative breast cancer.
Huang W; Wang C; Shen Y; Chen Q; Huang Z; Liu J; Lin X; Wang L; Wu F; Chen X; Li N; Hong Y; Chen M; Li J; Huang C
BMC Cancer; 2024 Jan; 24(1):39. PubMed ID: 38182995
[TBL] [Abstract][Full Text] [Related]
10. Apatinib for patients with advanced or recurrent cervical cancer: study protocol for an open-label randomized controlled trial.
Zhou JG; Zhou NJ; Zhang Q; Feng YY; Zhou H
Trials; 2018 Sep; 19(1):500. PubMed ID: 30223869
[TBL] [Abstract][Full Text] [Related]
11. Phase II and Biomarker Study of Cabozantinib in Metastatic Triple-Negative Breast Cancer Patients.
Tolaney SM; Ziehr DR; Guo H; Ng MR; Barry WT; Higgins MJ; Isakoff SJ; Brock JE; Ivanova EV; Paweletz CP; Demeo MK; Ramaiya NH; Overmoyer BA; Jain RK; Winer EP; Duda DG
Oncologist; 2017 Jan; 22(1):25-32. PubMed ID: 27789775
[TBL] [Abstract][Full Text] [Related]
12. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
[TBL] [Abstract][Full Text] [Related]
13. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
[TBL] [Abstract][Full Text] [Related]
14. Apatinib plus vinorelbine versus vinorelbine for metastatic triple-negative breast cancer who failed first/second-line treatment: the NAN trial.
Li DD; Tao ZH; Wang BY; Wang LP; Cao J; Hu XC; Zhang J
NPJ Breast Cancer; 2022 Sep; 8(1):110. PubMed ID: 36127351
[TBL] [Abstract][Full Text] [Related]
15. Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.
Hu X; Zhang J; Xu B; Jiang Z; Ragaz J; Tong Z; Zhang Q; Wang X; Feng J; Pang D; Fan M; Li J; Wang B; Wang Z; Zhang Q; Sun S; Liao C
Int J Cancer; 2014 Oct; 135(8):1961-9. PubMed ID: 24604288
[TBL] [Abstract][Full Text] [Related]
16. Low-dose apatinib combined with neoadjuvant chemotherapy in the treatment of early-stage triple-negative breast cancer (LANCET): a single-center, single-arm, phase II trial.
Yang C; Zhang J; Zhang Y; Ji F; Chen Y; Zhu T; Zhang L; Gao H; Yang M; Li J; Cheng M; Wang K
Ther Adv Med Oncol; 2022; 14():17588359221118053. PubMed ID: 35983024
[TBL] [Abstract][Full Text] [Related]
17. A phase II clinical trial of the Aurora and angiogenic kinase inhibitor ENMD-2076 for previously treated, advanced, or metastatic triple-negative breast cancer.
Diamond JR; Eckhardt SG; Pitts TM; van Bokhoven A; Aisner D; Gustafson DL; Capasso A; Sams S; Kabos P; Zolman K; Colvin T; Elias AD; Storniolo AM; Schneider BP; Gao D; Tentler JJ; Borges VF; Miller KD
Breast Cancer Res; 2018 Aug; 20(1):82. PubMed ID: 30071865
[TBL] [Abstract][Full Text] [Related]
18. Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study.
Li YH; Zhou Y; Wang YW; Tong L; Jiang RX; Xiao L; Zhang GJ; Xing SS; Qian F; Feng JQ; Zhao YL; Wang JG; Wang XH
Medicine (Baltimore); 2018 Sep; 97(36):e12222. PubMed ID: 30200142
[TBL] [Abstract][Full Text] [Related]
19. Apatinib plus etoposide in pretreated patients with advanced triple-negative breast cancer: a phase II trial.
Cao M; Lu H; Yan S; Pang H; Sun L; Li C; Chen X; Liu W; Hu J; Huang J; Xing Y; Zhang N; Chen Y; He T; Zhao D; Sun Y; Zhao L; Liu X; Cai L
BMC Cancer; 2023 May; 23(1):463. PubMed ID: 37208633
[TBL] [Abstract][Full Text] [Related]
20. Apatinib combined with chemotherapy or concurrent chemo-brachytherapy in patients with recurrent or advanced cervical cancer: A phase 2, randomized controlled, prospective study.
Guo Q; Sun Y; Kong E; Rao L; Chen J; Wu Q; Zhang T; Liu N; Li M; Sun L
Medicine (Baltimore); 2020 Mar; 99(11):e19372. PubMed ID: 32176061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
